债券受托管理人z 。！：？！�贯费 （海口市南沙路49号通信广场二楼〉 二O二三年十月 股票代码：603579.SH 债券代码：113606.SH 股票简称：荣泰健康 债券简称：荣泰转债 上海荣泰健康科技股份有限公司 2020年可转换公司债券 临时受托管理事务报告 (2023年第七期〉 u '七＼ 重要声明 a 气 t 万和证券股份有限公司（以下简称"万和证券"）编制本报告的内容及信息来 源于上海荣泰健康科技股份有限公司（以下简称"荣泰健康" 、 "公司"或 "发行人" ） 对外公布的公开信息披露文件以及发行人向万和证券提供的资料。 万和证券按照《公司债券发行与交易管理办法》《公司债券受托管理人执业 行为准则》等相关规定及与荣泰健康签订的《受托管理协议》约定编制本报告。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为万和证券所作的承诺 或声明。请投资者独立征询专业机构意见，在任何情况下，投资者不能将本报告 作为投资行为依据。 万和证券提请投资者及时关注发行人的信息披露文件，并己督促发行人及时 履行信息披露义务。 债券代码：113606. ...

转债代码：113606 转债简称：荣泰转债 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海荣泰健康科技股份有限公司（以下简称"公司"）于 2020 年 10 月 30 日公开发行的可转换公司债券（以下简称"本期债券"或"荣泰转债"），将于 2023 年 10 月 30 日支付自 2022 年 10 月 29 日至 2023 年 10 月 28 日期间的利息。 根据《上海荣泰健康科技股份有限公司公开发行可转换公司债券募集说明书》（以 下简称"《募集说明书》"）及《上海荣泰健康科技股份有限公司公开发行可转 换公司债券上市公告书》（以下简称"《上市公告书》"）有关条款的规定，现 将有关事项公告如下： 一、本期债券基本情况 可转债付息债权登记日：2023 年 10 月 27 日 可转债除息日：2023 年 10 月 30 日 可转债付息日：2023 年 10 月 30 日 证券代码：603579 证券简称：荣泰健康 公告编号：2023-055 上海荣泰健康科技股份有限公司 关于"荣泰转债"2023 年付息的公告 ...

一、2023 年 8 月 23 日至本公告日，公司使用部分闲置募集资金进行现金管 理到期赎回的情况 公司于 2023 年 8 月 23 日使用可转债闲置募集资金 3,400 万元人民币购买了 中国民生银行股份有限公司的 FGG2336001/2023 年对公大额存单第 1期（3 年）， 具体内容详见公司于 2023 年 8 月 24 日披露的《上海荣泰健康科技股份有限公司 关于使用可转债闲置募集资金进行现金管理的进展公告》（公告编号：2023-049）。 公司已于 2023 年 10 月 17 日将购买上述理财产品的本金 3,400 万元及收益 75.86 万元全部收回。 特此公告。 上海荣泰健康科技股份有限公司董事会 2023 年 10 月 18 日 | 证券代码：603579 | 证券简称：荣泰健康 公告编号：2023-053 | | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | 上海荣泰健康科技股份有限公司 关于使用可转债闲置募集资金进行现金管理到期赎 回的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | 重要内容提示： 累计转股情况："荣泰转债"自 2021 年 5 月 6 日进入转股期，截至 2023 年 9 月 30 日，累计有人民币 143,000 元"荣泰转债"转换为公司普通股股票， 累计转股数量 4,371 股，占"荣泰转债"转股前公司已发行股份总额的 0.00312%。 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 关于公司可转债转股结果暨股份变动公告 未转股可转债情况：截至 2023 年 9 月 30 日，尚未转股的"荣泰转债" 金额为人民币 599,857,000 元，占"荣泰转债"发行总量的 99.9762%。 本季度转股情况：自 2023 年 7 月 1 日至 2023 年 9 月 30 日，共有人民币 12,000 元"荣泰转债"转换为公司普通股股票，转股数量 379 股。 一、可转债发行上市概况 （一） 可转债发行情况 经中国证券监督管理委员会《关于核准上海荣泰健康科技股份有限公司公开 发行可转换公司债券的批复》（证 ...

| 证券代码：603579 | 证券简称：荣泰健康 公告编号：2023-050 | | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | 上海荣泰健康科技股份有限公司 关于参与认购私募股权投资基金份额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （1）由于股权投资合伙企业具有投资周期长、流动性低的特点，公司本次 投资可能面临较长的投资回收期； （2）受宏观经济的影响、投资标的的选择、行业环境以及基金自身管理和 技术等多种因素影响，存在不能实现预期效益的风险； （3）合伙企业设立运营后，存在因国家政策、法律法规、宏观经济影响、 行业宏观环境、投资标的选择以及投资管理不确定性，无法达成预期收益或亏损 的风险，但公司作为合伙企业的有限合伙人，承担的投资风险敞口不超过公司出 资额，即 2,000 万元人民币，敬请广大投资者注意投资风险。 一、对外投资概述 （一）对外投资的基本情况 上海荣泰健康科技股份有限公司（以下简称"公司"）在确保满足日常经营 资金需求、总体投资风险可控的前提 ...

| 证券代码：603579 | 证券简称：荣泰健康 公告编号：2023-048 | | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | 上海荣泰健康科技股份有限公司 关于公司参与投资创业基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （1）本次对外投资相关文件尚未完成签署，协议内容和具体操作方式以各 方最终签署的正式协议为准，本事项实施过程尚存在一定的不确定性； （2）受宏观经济的影响、投资标的的选择、行业环境以及基金自身管理和 技术等多种因素影响，存在不能实现预期效益的风险； （3）创业投资基金对外投资过程中将受国家政策、税收、经济周期、投资 标的经营管理、投资标的的境外投资审批手续无法完成、投资标的境外投资退出 时的汇率波动等多种因素影响，亦可能面临基金合同与中国基金业协会合同指引 不一致、基金运营、流动性、税收政策变化、投资标的选择不当、决策失误、投 资失败及亏损等风险；但公司作为合伙企业的有限合伙人，承担的投资风险敞口 不超过公司出资额，即 1,000 万元人 ...

| 证券代码：603579 | 证券简称：荣泰健康 公告编号：2023-047 | | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | 上海荣泰健康科技股份有限公司 关于使用可转债闲置募集资金进行现金管理的进展 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：可转让大额存单 投资金额：人民币 8,800 万元 现金管理期限：持有该存单期限不超过 12 个月 已履行的审议程序：上海荣泰健康科技股份有限公司（以下简称"公司"） 于 2023 年 4 月 6 日召开第四届董事会第五次会议、第四届监事会第四次会 议，于 2023 年 5 月 5 日召开 2022 年年度股东大会，分别审议通过了《关于 公司 2023 年度使用可转债闲置募集资金进行现金管理的议案》，同意公司 及子公司使用最高不超过人民币 3 亿元的公开发行可转换公司债券（以下简 称"可转债"）闲置募集资金适时投资安全性高、流动性好、有保本约定的理 财产品或结构性存款，授权期限为自公司 2022 年年度股东大 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately RMB 889.90 million, a decrease of 19.20% compared to RMB 1,101.36 million in the same period last year[19]. - Net profit attributable to shareholders for the first half of 2023 was approximately RMB 104.92 million, an increase of 21.48% from RMB 86.37 million in the previous year[19]. - The net profit after deducting non-recurring gains and losses was approximately RMB 95.61 million, up 19.63% from RMB 79.92 million in the same period last year[19]. - Basic earnings per share for the first half of 2023 were RMB 0.78, representing a 20.00% increase from RMB 0.65 in the same period last year[19]. - Diluted earnings per share for the first half of 2023 were RMB 0.77, an increase of 20.31% from RMB 0.64 in the previous year[19]. - The company reported a total comprehensive income of 54,380.62 million RMB for the first half of 2023, reflecting a significant increase compared to the previous period[179]. - The net profit attributable to shareholders for the first half of 2023 was 95,658.44 million, showing a growth of 6.10% compared to the previous year[172]. Cash Flow and Assets - The net cash flow from operating activities increased by 66.67% to approximately RMB 164.08 million, compared to RMB 98.45 million in the previous year[19]. - The company's cash and cash equivalents at the end of the period were 1.22 billion RMB, accounting for 36.89% of total assets, a decrease of 8.10% from the previous year[54]. - The company's cash and cash equivalents as of June 30, 2023, are 1,222,105,262.83 yuan, down from 1,329,776,484.49 yuan at the end of 2022[137]. - The total current assets decreased from 2,270,578,335.21 yuan to 2,023,612,212.08 yuan[137]. - The total assets of the company at the end of the first half of 2023 were reported at 3,941,290.0 million, compared to 3,776,170.3 million at the end of the previous year, marking a growth of approximately 4.36%[169]. - The total assets of the company reached 3,896,930 million, demonstrating growth in asset base[161]. Investment and Expansion - The company has established over 1,000 offline stores in China and maintains a presence on major e-commerce platforms such as Tmall, JD.com, and Douyin[40]. - The company aims to provide a healthy and fashionable lifestyle for global users, aligning with its vision of serving millions of families[28]. - The company plans to adjust its product strategy and implement proactive sales policies to boost overseas orders in response to varying market conditions[46]. - The company is actively developing new products in collaboration with ODM partners and expanding its market presence beyond Korea to other regions[81]. - The company plans to expand its market presence and invest in new product development to drive future growth[147]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[171]. Research and Development - The company completed 9 R&D projects and obtained 6 new invention patents, 51 utility model patents, and 11 design patents during the reporting period[48]. - The company aims to enhance its research and development efforts to innovate and improve product offerings[162]. - The company has initiated research and development for new technologies aimed at enhancing operational efficiency and customer engagement[171]. Market Trends and Strategies - The global massage equipment market is projected to reach approximately $23.6 billion by 2026, driven by increasing health awareness and disposable income in China[27]. - The domestic market shows a strong trend in consumer spending on massage and health care products, with significant growth in both domestic and international orders[41]. - The company employs an order-based production model, ensuring efficient management of manufacturing processes[38]. - The company utilizes a dual sales model for domestic and international markets, with a focus on ODM for global brands[34]. - The massage equipment industry is characterized by rapid technological advancements, integrating various high-tech fields[27]. Financial Management and Risks - The company faces risks from raw material price fluctuations, as over 80% of its cost structure is attributed to raw materials, which could impact net profit growth if prices rise significantly[79]. - The company has a significant reliance on BODYFRIEND, with its sales contributing a substantial portion of revenue; any adverse changes in this relationship could negatively affect performance[80]. - The company is managing foreign exchange risks through various strategies, including settling contracts in RMB and using hedging tools[83]. - The company emphasizes a diversified procurement strategy to mitigate risks associated with raw material shortages[39]. Shareholder and Stock Information - The total number of shareholders reached 12,065 by the end of the reporting period[115]. - The company has 138,973,433 unrestricted circulating shares, accounting for 99.29% of total shares[109]. - The top ten shareholders hold a total of 100,000,000 shares, with Lin Qi holding 34,900,230 shares (25.11%) and Lin Guangrong holding 21,499,870 shares (15.47%) [117]. - The company has approved a foreign exchange derivative trading limit of up to USD 300 million, with a current position accounting for 13.20% of this limit[68]. - The company announced the repurchase and cancellation of 1,000,000 restricted stock units due to unmet performance conditions in the 2021 incentive plan[90]. Legal and Compliance - The company is currently involved in a lawsuit with a claim for economic damages of 99 million yuan related to patent infringement on massage chairs, with the case still pending judgment[105]. - The company’s revenue recognition and accounting policies are in accordance with the relevant enterprise accounting standards, ensuring accurate financial reporting[190].

关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 08 月 08 日（星期二）至 08 月 14 日（星期一）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 Public@rotai.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 上海荣泰健康科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 8 日 发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年 半年度经营成果、财务状况，公司计划于 2023 年 08 月 15 日上午 10:00-11:00 举 行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 | 证券代码：603579 | 证券简称：荣泰健康 公告编号：2023-046 | | --- | --- | | 转债代码：113606 | ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥385,718,637.33, representing a decrease of 31.71% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was ¥37,501,251.13, down 35.70% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,866,712.47, a decline of 39.52% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.28, reflecting a decrease of 36.36% year-over-year[6] - The diluted earnings per share for Q1 2023 was also ¥0.28, down 33.33% from the same period last year[6] - Total operating revenue for Q1 2023 was CNY 385.72 million, a decrease of 31.7% compared to CNY 564.80 million in Q1 2022[19] - Net profit for Q1 2023 was CNY 37.68 million, a decline of 35.6% from CNY 58.56 million in Q1 2022[20] - Basic earnings per share for Q1 2023 were CNY 0.28, compared to CNY 0.44 in Q1 2022[21] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,259,730,630.27, down 4.79% from the end of the previous year[6] - Total assets as of Q1 2023 were CNY 3.26 billion, a decrease from CNY 3.42 billion at the end of Q1 2022[16] - Total liabilities as of Q1 2023 were CNY 1.35 billion, down from CNY 1.55 billion in Q1 2022[16] - Shareholders' equity attributable to the parent company was ¥1,903,618,815.29, an increase of 2.01% compared to the end of the previous year[6] - Shareholders' equity as of Q1 2023 was CNY 1.91 billion, an increase from CNY 1.87 billion in Q1 2022[17] Cash Flow - The company reported a net cash flow from operating activities of ¥21,078,065.76 for Q1 2023, with no applicable year-over-year comparison[5] - The net cash flow from operating activities for Q1 2023 was 21,078,065.76, a significant improvement from -27,415,890.24 in Q1 2022, indicating a recovery in operational efficiency[24] - Total cash inflow from operating activities was 448,101,157.18, while cash outflow was 427,023,091.42, resulting in a net cash inflow of 21,078,065.76 for the quarter[24] - Cash received from sales of goods and services in Q1 2023 was CNY 392.97 million, down 33.2% from CNY 589.07 million in Q1 2022[23] - The total cash and cash equivalents at the end of Q1 2023 were 1,242,747,863.10, down from 1,284,376,555.91 at the end of Q1 2022[25] Investments and Expenses - Research and development expenses for Q1 2023 were CNY 17.23 million, a decrease of 31.5% from CNY 25.17 million in Q1 2022[19] - Financial expenses for Q1 2023 were CNY 5.39 million, compared to CNY 4.86 million in Q1 2022[20] - Cash inflow from investment activities was 237,989,336.56, compared to 612,494,044.13 in the previous year, reflecting a decrease in investment returns[25] - The cash outflow for investment activities was 194,998,606.79, down from 542,435,408.90 in Q1 2022, suggesting a reduction in capital expenditures[25] Legal Matters - The company is currently involved in a legal dispute with a claim for economic damages of RMB 99 million related to patent infringement, which is still pending court judgment[13] - The company has taken proactive measures to respond to the ongoing litigation and is contesting the claims made against it[13] - The company has not provided specific guidance for future performance in this report, but it is actively monitoring market conditions and legal developments[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,229[10] - The company reported a total of 3,348,479 shares held in its repurchase account, accounting for 2.39% of the total shares as of March 31, 2023[12] Other Financial Metrics - The weighted average return on equity for Q1 2023 was 1.99%, a decrease of 1.24 percentage points compared to the end of the previous year[6] - As of March 31, 2023, the company's cash and cash equivalents amounted to RMB 1,242,747,863.10, a decrease from RMB 1,329,776,484.49 as of December 31, 2022, representing a decline of approximately 6.5%[14] - The total current assets as of March 31, 2023, were RMB 2,038,128,218.89, down from RMB 2,270,578,335.21 at the end of 2022, indicating a decrease of about 10.2%[15] - The company's accounts receivable increased to RMB 106,227,100.14 from RMB 95,069,521.56, reflecting a growth of approximately 11.4%[15] - The inventory level decreased to RMB 177,040,326.87 from RMB 205,227,948.56, showing a reduction of around 13.7%[15] - Long-term equity investments were reported at RMB 58,586,718.35, slightly down from RMB 59,082,899.43, indicating a decrease of about 0.8%[15] - The total non-current assets as of March 31, 2023, were RMB 1,221,602,411.38, an increase from RMB 1,153,246,826.81 at the end of 2022, representing a growth of approximately 5.9%[15]